RU2002110281A - Производные трет-бутил(7-метилимидазол[1,2-а]пиридин-3-ил)амина - Google Patents
Производные трет-бутил(7-метилимидазол[1,2-а]пиридин-3-ил)аминаInfo
- Publication number
- RU2002110281A RU2002110281A RU2002110281/04A RU2002110281A RU2002110281A RU 2002110281 A RU2002110281 A RU 2002110281A RU 2002110281/04 A RU2002110281/04 A RU 2002110281/04A RU 2002110281 A RU2002110281 A RU 2002110281A RU 2002110281 A RU2002110281 A RU 2002110281A
- Authority
- RU
- Russia
- Prior art keywords
- unsubstituted
- mono
- pyridin
- tert
- unsaturated
- Prior art date
Links
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 title claims 10
- 150000001412 amines Chemical class 0.000 title claims 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 title claims 10
- 229920006395 saturated elastomer Polymers 0.000 claims 54
- -1 tert-butyl [2- (2,3-dimethoxyphenyl) -5,7-dimethylimidazo [1,2-a] pyridin-3yl] amine Chemical class 0.000 claims 30
- 125000003118 aryl group Chemical group 0.000 claims 28
- 125000001072 heteroaryl group Chemical group 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 125000000623 heterocyclic group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 13
- 125000002877 alkyl aryl group Chemical group 0.000 claims 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 8
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 8
- 238000006073 displacement reaction Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- NNGDTFNYWWYMKI-UHFFFAOYSA-N 3-[3-(tert-butylamino)-5,7-dimethylimidazo[1,2-a]pyridin-2-yl]phenol Chemical compound N1=C2C=C(C)C=C(C)N2C(NC(C)(C)C)=C1C1=CC=CC(O)=C1 NNGDTFNYWWYMKI-UHFFFAOYSA-N 0.000 claims 3
- UQMMDAXQSRVVDM-UHFFFAOYSA-N 3-[3-(tert-butylamino)-7-methylimidazo[1,2-a]pyridin-2-yl]phenol Chemical compound N1=C2C=C(C)C=CN2C(NC(C)(C)C)=C1C1=CC=CC(O)=C1 UQMMDAXQSRVVDM-UHFFFAOYSA-N 0.000 claims 3
- DXGSPAYUJRCIKT-UHFFFAOYSA-N 5-[3-(tert-butylamino)-5,7-dimethylimidazo[1,2-a]pyridin-2-yl]furan-2-carboxylic acid Chemical compound N1=C2C=C(C)C=C(C)N2C(NC(C)(C)C)=C1C1=CC=C(C(O)=O)O1 DXGSPAYUJRCIKT-UHFFFAOYSA-N 0.000 claims 3
- RCQFFBBGAATMLI-UHFFFAOYSA-N 5-[3-(tert-butylamino)-7-methylimidazo[1,2-a]pyridin-2-yl]thiophene-2-carboxylic acid Chemical compound N1=C2C=C(C)C=CN2C(NC(C)(C)C)=C1C1=CC=C(C(O)=O)S1 RCQFFBBGAATMLI-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 201000006474 Brain Ischemia Diseases 0.000 claims 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010065390 Inflammatory pain Diseases 0.000 claims 3
- 201000009906 Meningitis Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010040070 Septic Shock Diseases 0.000 claims 3
- XBIJCAKRLAMAPN-UHFFFAOYSA-N [5-[3-(tert-butylamino)-7-methylimidazo[1,2-a]pyridin-2-yl]furan-2-yl]methanol Chemical compound N1=C2C=C(C)C=CN2C(NC(C)(C)C)=C1C1=CC=C(CO)O1 XBIJCAKRLAMAPN-UHFFFAOYSA-N 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- 206010008118 cerebral infarction Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 230000036303 septic shock Effects 0.000 claims 3
- 230000029663 wound healing Effects 0.000 claims 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 150000003927 aminopyridines Chemical class 0.000 claims 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- FAGLEPBREOXSAC-UHFFFAOYSA-N tert-butyl isocyanide Chemical compound CC(C)(C)[N+]#[C-] FAGLEPBREOXSAC-UHFFFAOYSA-N 0.000 claims 1
- 239000005051 trimethylchlorosilane Substances 0.000 claims 1
- 0 CC(C)(C)Nc1c(*)nc2[n]1c(*)cc(C)c2C Chemical compound CC(C)(C)Nc1c(*)nc2[n]1c(*)cc(C)c2C 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19948434.1 | 1999-10-08 | ||
| DE19948434A DE19948434A1 (de) | 1999-10-08 | 1999-10-08 | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002110281A true RU2002110281A (ru) | 2003-12-20 |
Family
ID=7924888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002110281/04A RU2002110281A (ru) | 1999-10-08 | 2000-10-06 | Производные трет-бутил(7-метилимидазол[1,2-а]пиридин-3-ил)амина |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6703404B2 (https=) |
| EP (1) | EP1218378B1 (https=) |
| JP (1) | JP2003511450A (https=) |
| KR (1) | KR100793619B1 (https=) |
| CN (1) | CN1208336C (https=) |
| AR (2) | AR025960A1 (https=) |
| AT (1) | ATE238304T1 (https=) |
| AU (2) | AU7419900A (https=) |
| BR (1) | BR0014827A (https=) |
| CA (1) | CA2386804A1 (https=) |
| CO (2) | CO5210861A1 (https=) |
| CZ (1) | CZ20021241A3 (https=) |
| DE (2) | DE19948434A1 (https=) |
| DK (1) | DK1218378T3 (https=) |
| ES (1) | ES2198355T3 (https=) |
| HK (1) | HK1047749B (https=) |
| HU (1) | HUP0203545A3 (https=) |
| IL (3) | IL148997A0 (https=) |
| MX (1) | MXPA02003546A (https=) |
| NO (1) | NO20021564L (https=) |
| NZ (1) | NZ518438A (https=) |
| PE (2) | PE20010632A1 (https=) |
| PL (1) | PL355109A1 (https=) |
| PT (1) | PT1218378E (https=) |
| RU (1) | RU2002110281A (https=) |
| SK (1) | SK4622002A3 (https=) |
| WO (2) | WO2001027119A2 (https=) |
| ZA (2) | ZA200203579B (https=) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083966A (en) | 1998-08-31 | 2000-07-04 | University Of Florida | Thiazoline acid derivatives |
| CN1585639A (zh) | 1998-09-21 | 2005-02-23 | 佛罗里达大学研究基金会 | 抗疟疾制剂 |
| WO2001076694A1 (en) | 2000-04-10 | 2001-10-18 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| DE10043845A1 (de) * | 2000-09-06 | 2002-03-14 | Gruenenthal Gmbh | Verfahren zur Messung der Aktivität der NO-Synthase |
| DE10050663A1 (de) * | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| AU2002224927A1 (en) * | 2000-12-13 | 2002-06-24 | Basf Aktiengesellschaft | Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds |
| DE10117183A1 (de) * | 2001-04-05 | 2002-10-10 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel |
| DE10117184A1 (de) * | 2001-04-05 | 2002-10-17 | Gruenenthal Gmbh | Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen |
| DE10132726A1 (de) | 2001-07-05 | 2003-02-27 | Gruenenthal Gmbh | Verwendung von substituierten gamma-Lactonverbindungen als Arzneimittel |
| DK1483247T3 (da) | 2002-03-13 | 2009-08-17 | Euro Celtique Sa | Arylsubstituerede pyrimidiner og anvendelsen deraf |
| CA2482991A1 (en) | 2002-04-19 | 2003-10-30 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof |
| US20050197435A1 (en) * | 2002-06-14 | 2005-09-08 | Dotson Darin L. | Polymer additive compositions for bimolecular nucleation in thermoplastics |
| US7312341B2 (en) | 2002-09-09 | 2007-12-25 | Cgi Pharmaceuticals, Inc. | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof |
| DE10246890A1 (de) | 2002-10-08 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine |
| AU2003290333A1 (en) * | 2002-12-24 | 2004-07-22 | Biofocus Plc | Compound libraries of imidazo(1,5-a)pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors |
| WO2004072081A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| US7259164B2 (en) | 2003-08-11 | 2007-08-21 | Cgi Pharmaceuticals, Inc. | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity |
| WO2005034949A1 (en) | 2003-09-09 | 2005-04-21 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
| DE102004021716A1 (de) * | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
| DE102004044884A1 (de) | 2004-09-14 | 2006-05-24 | Grünenthal GmbH | Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen |
| US7820654B2 (en) | 2004-09-23 | 2010-10-26 | Dr. Reddy's Laboratories Ltd. | Pyrimidine compounds, process for their preparation and compositions containing them |
| TR201910900T4 (tr) | 2005-04-04 | 2019-08-21 | Univ Florida | Desferritiyokin polieter analogları. |
| DE102005016547A1 (de) * | 2005-04-08 | 2006-10-12 | Grünenthal GmbH | Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| WO2007024294A2 (en) | 2005-05-03 | 2007-03-01 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
| EP1902056A2 (en) | 2005-05-20 | 2008-03-26 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
| US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP1910385B1 (en) | 2005-08-04 | 2013-07-24 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7709468B2 (en) | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
| SI2495016T1 (sl) | 2005-12-23 | 2020-04-30 | Ariad Pharmaceuticals, Inc. | Biciklične heteroarilne spojine |
| DE102006011574A1 (de) | 2006-03-10 | 2007-10-31 | Grünenthal GmbH | Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln |
| ES2422890T3 (es) | 2006-03-17 | 2013-09-16 | Ambit Biosciences Corporation | Compuestos de imidazolotiazol para el tratamiento de enfermedades proliferativas |
| WO2008115433A1 (en) | 2007-03-15 | 2008-09-25 | University Of Florida | Desferrithiocin polyether analogues |
| WO2008134553A1 (en) * | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
| GB0708188D0 (en) * | 2007-04-27 | 2007-06-06 | Merck Sharp & Dohme | Therapeutic compounds |
| CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| DE102007040336A1 (de) * | 2007-08-27 | 2009-03-05 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen |
| CA2696776C (en) | 2007-09-19 | 2015-12-15 | Ambit Biosciences Corporation | Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
| JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ，インコーポレーテッド | ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法 |
| RS52561B (sr) * | 2008-04-15 | 2013-04-30 | Eisai R&D Management Co., Ltd. | Jedinjenje 3-fenilpirazolo[5,1-b]tiazol |
| WO2010032195A1 (en) | 2008-09-16 | 2010-03-25 | Csir | Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors |
| EA021293B1 (ru) | 2008-12-08 | 2015-05-29 | Джилид Коннектикут, Инк. | ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| CN102307474B (zh) | 2008-12-08 | 2015-04-01 | 吉利德康涅狄格股份有限公司 | 咪唑并吡嗪syk抑制剂 |
| EP2376502B1 (en) | 2008-12-19 | 2015-06-17 | GlaxoSmithKline LLC | Thiazolopyridine sirtuin modulating compounds |
| AR078521A1 (es) * | 2009-10-08 | 2011-11-16 | Eisai R&D Man Co Ltd | Compuesto pirazolotiazol |
| CN103168039B (zh) | 2010-03-11 | 2016-08-03 | 吉利德康涅狄格公司 | 咪唑并吡啶类syk抑制剂 |
| EP3620161A1 (en) | 2011-12-16 | 2020-03-11 | University of Florida Research Foundation, Inc. | Uses of 4'-desferrithiocin analogs |
| BR112014026651A8 (pt) | 2012-04-26 | 2018-01-16 | Bristol Myers Squibb Co | derivados de imidazotiadiazol e de imidazopiridazina como inibidores do receptor ativado por proteases 4 (par4) para o tratamento de agregação plaquetária |
| WO2013163244A1 (en) | 2012-04-26 | 2013-10-31 | Bristol-Myers Squibb Company | Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| LT2841437T (lt) | 2012-04-26 | 2017-09-11 | Bristol-Myers Squibb Company | Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuotų receptorių 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui |
| WO2014076021A1 (en) * | 2012-11-14 | 2014-05-22 | F. Hoffmann-La Roche Ag | Imidazopyridine derivatives |
| EA029281B1 (ru) | 2013-07-30 | 2018-03-30 | Джилид Коннектикут, Инк. | Полиморф ингибиторов syk |
| CA2919522C (en) | 2013-07-30 | 2019-02-26 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
| AU2014352780A1 (en) | 2013-11-22 | 2016-06-09 | University Of Florida Research Foundation, Inc. | Desferrithiocin analogs and uses thereof |
| CN105764516A (zh) | 2013-12-04 | 2016-07-13 | 吉利德科学公司 | 治疗癌症的方法 |
| TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| MX373103B (es) | 2014-02-13 | 2020-04-17 | Incyte Holdings Corp | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9617279B1 (en) | 2014-06-24 | 2017-04-11 | Bristol-Myers Squibb Company | Imidazooxadiazole compounds |
| US9598419B1 (en) | 2014-06-24 | 2017-03-21 | Universite De Montreal | Imidazotriazine and imidazodiazine compounds |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| BR112016028641A2 (pt) | 2014-07-14 | 2017-08-22 | Gilead Sciences Inc | ?método para tratar câncer? |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| KR20170140306A (ko) | 2015-04-27 | 2017-12-20 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도 |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| JP6999574B2 (ja) | 2016-04-22 | 2022-01-18 | インサイト・コーポレイション | Ｌｓｄ１阻害剤の製剤 |
| US11098043B2 (en) * | 2017-07-14 | 2021-08-24 | University Of Massachusetts | Certain imidazopyridines as cyclic AMP response element binding (CREB) binding protein (CBP) inhibitors and uses thereof |
| CA3073871A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| JP2020536853A (ja) * | 2017-10-04 | 2020-12-17 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 転写因子ｓａｌｌ４の小分子阻害およびその使用 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CN113950479A (zh) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | 作为syk抑制剂的缩合吡嗪的固体形式 |
| WO2024220541A1 (en) * | 2023-04-18 | 2024-10-24 | Kallyope, Inc. | Nk3 modulators and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3489755A (en) * | 1966-08-03 | 1970-01-13 | Pfizer & Co C | Imidazo (1,2-b) pyridazines |
| FR2463774A1 (fr) * | 1979-08-21 | 1981-02-27 | Yamanouchi Pharma Co Ltd | Derives du 2-phenylimidazo(2,1-b)benzothiazole |
| DE3269604D1 (en) * | 1981-06-26 | 1986-04-10 | Schering Corp | Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them |
| EP0266890A1 (en) * | 1986-10-07 | 1988-05-11 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them |
| FR2638161B1 (fr) * | 1988-10-24 | 1991-01-11 | Centre Nat Rech Scient | Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
| JPH08333258A (ja) * | 1994-12-14 | 1996-12-17 | Japan Tobacco Inc | チアジン又はチアゼピン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤 |
| GB9506188D0 (en) * | 1995-03-27 | 1995-05-17 | Fujisawa Pharmaceutical Co | Amidine derivatives |
| US5908842A (en) * | 1995-12-08 | 1999-06-01 | Merck & Co., Inc. | Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase |
| WO1998006724A1 (en) * | 1996-08-09 | 1998-02-19 | Yamanouchi Pharmaceutical Co., Ltd. | Metabotropic glutamate receptor agonists |
| AUPP278498A0 (en) * | 1998-04-03 | 1998-04-30 | Australian Nuclear Science & Technology Organisation | Peripheral benzodiazepine receptor binding agents |
-
1999
- 1999-10-08 DE DE19948434A patent/DE19948434A1/de not_active Withdrawn
-
2000
- 2000-09-18 AU AU74199/00A patent/AU7419900A/en not_active Abandoned
- 2000-09-18 WO PCT/EP2000/009098 patent/WO2001027119A2/de not_active Ceased
- 2000-09-18 IL IL14899700A patent/IL148997A0/xx not_active IP Right Cessation
- 2000-10-02 CO CO00074640A patent/CO5210861A1/es not_active Application Discontinuation
- 2000-10-05 AR ARP000105251A patent/AR025960A1/es not_active Application Discontinuation
- 2000-10-05 AR ARP000105250A patent/AR025959A1/es not_active Application Discontinuation
- 2000-10-06 BR BR0014827-0A patent/BR0014827A/pt not_active IP Right Cessation
- 2000-10-06 PL PL00355109A patent/PL355109A1/xx not_active IP Right Cessation
- 2000-10-06 ES ES00969439T patent/ES2198355T3/es not_active Expired - Lifetime
- 2000-10-06 DK DK00969439T patent/DK1218378T3/da active
- 2000-10-06 AU AU79153/00A patent/AU780526B2/en not_active Ceased
- 2000-10-06 CN CNB008167079A patent/CN1208336C/zh not_active Expired - Fee Related
- 2000-10-06 HU HU0203545A patent/HUP0203545A3/hu unknown
- 2000-10-06 JP JP2001530327A patent/JP2003511450A/ja active Pending
- 2000-10-06 CA CA002386804A patent/CA2386804A1/en not_active Abandoned
- 2000-10-06 NZ NZ518438A patent/NZ518438A/en not_active IP Right Cessation
- 2000-10-06 CO CO00076179A patent/CO5251429A1/es not_active Application Discontinuation
- 2000-10-06 KR KR1020027004518A patent/KR100793619B1/ko not_active Expired - Fee Related
- 2000-10-06 AT AT00969439T patent/ATE238304T1/de active
- 2000-10-06 DE DE50001911T patent/DE50001911D1/de not_active Expired - Lifetime
- 2000-10-06 CZ CZ20021241A patent/CZ20021241A3/cs unknown
- 2000-10-06 MX MXPA02003546A patent/MXPA02003546A/es active IP Right Grant
- 2000-10-06 RU RU2002110281/04A patent/RU2002110281A/ru not_active Application Discontinuation
- 2000-10-06 EP EP00969439A patent/EP1218378B1/de not_active Expired - Lifetime
- 2000-10-06 IL IL14899900A patent/IL148999A0/xx active IP Right Grant
- 2000-10-06 HK HK02109385.2A patent/HK1047749B/zh not_active IP Right Cessation
- 2000-10-06 PE PE2000001063A patent/PE20010632A1/es not_active Application Discontinuation
- 2000-10-06 WO PCT/EP2000/009791 patent/WO2001027109A2/de not_active Ceased
- 2000-10-06 SK SK462-2002A patent/SK4622002A3/sk unknown
- 2000-10-06 PT PT00969439T patent/PT1218378E/pt unknown
- 2000-10-06 PE PE2000001062A patent/PE20010706A1/es not_active Application Discontinuation
-
2002
- 2002-04-03 NO NO20021564A patent/NO20021564L/no not_active Application Discontinuation
- 2002-04-04 IL IL148999A patent/IL148999A/en not_active IP Right Cessation
- 2002-04-08 US US10/117,339 patent/US6703404B2/en not_active Expired - Fee Related
- 2002-05-06 ZA ZA200203579A patent/ZA200203579B/xx unknown
- 2002-05-06 ZA ZA200203581A patent/ZA200203581B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002110281A (ru) | Производные трет-бутил(7-метилимидазол[1,2-а]пиридин-3-ил)амина | |
| JP2003511450A5 (https=) | ||
| DE69834508T2 (de) | Apoptoseinhibitoren | |
| RU2005109913A (ru) | Азабициклоалкильные эфиры и их применение в качестве агонистов альфа7-nachr | |
| RU2012117398A (ru) | Бензоксазепиновые ингибиторы pi3 и способы применения | |
| JP5896601B2 (ja) | セラミド誘導体を用いる多発性嚢胞腎疾患の治療方法 | |
| JP2017517508A (ja) | ボロン酸誘導体およびその治療的使用 | |
| JP2015003909A (ja) | ベンゾピラン化合物の組合せ、その組成物および使用 | |
| JP2013510124A5 (https=) | ||
| JP2020097596A5 (https=) | ||
| JP2005527576A5 (https=) | ||
| RU2002130247A (ru) | Производные оксадиазола, обладающие противоопухолевым действием | |
| AU2016282151B2 (en) | C,O-Spiro aryl glycoside compounds, preparation therefor and use thereof | |
| JP2002532503A5 (https=) | ||
| WO1999009965A2 (en) | Anti-inflammatory agent | |
| JP2002505276A (ja) | 潰瘍用医薬組成物 | |
| RU2009128970A (ru) | Производные изосорбидмононитрата для лечения кишечных заболеваний | |
| EP3994138B1 (en) | Estrogen-related receptor alpha (erralpha) modulators | |
| JP4904659B2 (ja) | ヒドロキシホルムアミジン誘導体及びそれらを含む医薬 | |
| JPH08505362A (ja) | Ｐａｆレセプター拮抗剤及び５−リポキシゲナーゼ阻害剤としての、２，４−ジアリール−１，３−ジチオラン、２，４−ジアリール−１，３−ジオキソラン、２，４−ジアリール−１，３−オキサチオラン、及び２，５−ジアリール−１，３−オキサチオラン | |
| US20140235584A1 (en) | Biaryl heterocycle substituted oxazolidinone antibacterial agents | |
| RU2016109792A (ru) | Новые соединения-антагонисты рецептора нейрокинина-1 | |
| JP4045099B2 (ja) | ２０−ｈｅｔｅ産生酵素阻害剤 | |
| RU2002103301A (ru) | Производные индола | |
| WO2002013864A1 (en) | Medicinal compositions for preventing and treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20050518 |